1302 Stock Overview
An investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
LifeTech Scientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.47 |
| 52 Week High | HK$2.39 |
| 52 Week Low | HK$1.24 |
| Beta | 0.83 |
| 1 Month Change | -0.68% |
| 3 Month Change | 2.08% |
| 1 Year Change | -32.26% |
| 3 Year Change | -58.00% |
| 5 Year Change | 0% |
| Change since IPO | -26.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1302 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -2.0% | -1.6% | -0.5% |
| 1Y | -32.3% | -27.9% | 19.9% |
Return vs Industry: 1302 underperformed the Hong Kong Medical Equipment industry which returned -27.9% over the past year.
Return vs Market: 1302 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 1302 volatility | |
|---|---|
| 1302 Average Weekly Movement | 10.2% |
| Medical Equipment Industry Average Movement | 9.0% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 1302 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1302's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,414 | Yuehui Xie | www.lifetechmed.com |
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders worldwide. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, HeartR, and Konar-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; Futhrough endovascular needle systems; delivery systems, such as Fustar steerable and SteerEase introducers; Zoetrack guidewire; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; HearTone implantable cardiac pacing system; and SeQure snare systems, as well as pacemakers.
LifeTech Scientific Corporation Fundamentals Summary
| 1302 fundamental statistics | |
|---|---|
| Market cap | HK$6.81b |
| Earnings (TTM) | HK$264.98m |
| Revenue (TTM) | HK$1.36b |
25.7x
P/E Ratio5.0x
P/S RatioIs 1302 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1302 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.28b |
| Cost of Revenue | CN¥274.29m |
| Gross Profit | CN¥1.01b |
| Other Expenses | CN¥757.58m |
| Earnings | CN¥248.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.054 |
| Gross Margin | 78.58% |
| Net Profit Margin | 19.42% |
| Debt/Equity Ratio | 2.9% |
How did 1302 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 18:43 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
LifeTech Scientific Corporation is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wai Chak Yuen | BOCI Research Ltd. |
| Yuan Gao | China International Capital Corporation Limited |
| Hanqing Zhu | Guosen Securities Co., Ltd. |